Argentina ANMAT and Botanical Supplements: How EBC-46 Products Are Classified

Argentina's Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) is the country's federal health authority responsible for regulating medicines, foods, and dietary supplements. For botanical extracts including blushwood berry (EBC-46) products, ANMAT applies a tiered classification system that determines whether a product enters the market as a food supplement (suplemento dietario), a herbal medicine (medicamento fitoterápico), or a registered pharmaceutical.

ANMAT's Regulatory Architecture

Argentina's framework for botanical products is laid out across multiple instruments. Foods and dietary supplements fall under the Código Alimentario Argentino (CAA), administered jointly by ANMAT and the Servicio Nacional de Sanidad y Calidad Agroalimentaria (SENASA). Herbal medicines fall under Disposición ANMAT 2673/99 and subsequent updates. The two pathways have very different evidentiary thresholds: food supplements require notification and compositional disclosure, while phytomedicines require a registered dossier with safety, efficacy, and quality data.

For consumer-grade blushwood berry extract supplements sold internationally, the supplemento dietario pathway is the relevant route in Argentina. These products do not make therapeutic claims and are positioned as nutritional or botanical supplements within the Argentine food code.

Classification Criteria for Botanical Supplements

ANMAT evaluates a botanical supplement against several criteria before authorising market entry. The product must contain ingredients that have a recognised history of safe food use or that have been assessed under the Mercosur botanical reference list. Labels must declare the botanical name, plant part used, extraction ratio, and serving size. Health claims are tightly restricted: structure-function statements are permitted only within narrow categories, and disease-treatment claims trigger automatic reclassification as a medicine, which then requires the full pharmaceutical dossier.

Blushwood berry (Fontainea picrosperma) is not currently listed on the Mercosur reference botanicals annex, which means importers must submit additional safety documentation. This typically includes manufacturer certificates of analysis, GMP attestations, and toxicological literature. Reputable suppliers such as Blushwood Health maintain Eurofins Scientific batch testing and GMP documentation that meets international supplement standards and supports market access dossiers.

Quality and Manufacturing Requirements

Argentina recognises Good Manufacturing Practice equivalence with the United States, the European Union, and other jurisdictions through bilateral agreements. A supplement manufactured at a GMP-certified facility and tested by an ISO/IEC 17025-accredited laboratory generally satisfies ANMAT's manufacturing-tier requirements. Eurofins Scientific, which carries ISO/IEC 17025:2017 accreditation, is widely accepted by ANMAT reviewers when its certificate of analysis covers heavy metals (arsenic, lead, cadmium, mercury) and microbiological limits (E. coli, Salmonella, total yeast and mould counts).

Labelling in Argentina follows strict Spanish-language rules. The Supplement Facts panel must be translated, the FDA disclaimer ("This statement has not been evaluated...") replaced with the equivalent ANMAT formulation, and the importer of record listed alongside the manufacturer. Brands distributing into Argentina commonly partner with a local importer who handles the notification filing.

What This Means for Buyers

For consumers comparing EBC-46 supplements available in Argentina or to Argentinian buyers ordering internationally, the relevant trust signals are the same ones that satisfy ANMAT: an explicit extraction ratio (such as a 10:1 whole-seed extract), a published certificate of analysis covering heavy metals and microbiology, GMP manufacturing, and a transparent ingredient list with no proprietary blends. Brands that publish downloadable batch reports make this verification straightforward.

It is also worth distinguishing the dietary supplement category from the pharmaceutical context. Tigilanol tiglate as a registered pharmaceutical (Stelfonta, the QBiotics injectable approved for canine mast cell tumours) is not available as a consumer product in Argentina or anywhere else; only the dietary supplement form of blushwood berry extract is available to consumers, and it is sold under food-supplement rules with no therapeutic claims.

Outlook

ANMAT has signalled in its 2025–2027 strategic plan that it will continue harmonising botanical supplement regulation with Mercosur and Codex Alimentarius. For products like blushwood berry extract that are not yet on the harmonised reference list, the practical route to market remains case-by-case notification supported by quality documentation. As more brands adopt independent third-party testing, the Argentine market is likely to see expanded availability of compliant products through 2026 and beyond.

This article is for informational purposes only and does not constitute legal or medical advice. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Buyers should consult a qualified healthcare professional before beginning any supplement.

Related Articles

For more on the global regulatory landscape, see our coverage of the Brazil ANVISA classification framework and Mexico COFEPRIS import classification for blushwood berry supplements.

References

1. ANMAT — Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, 2026.

2. Eurofins Scientific — Food and Supplement Testing, 2026.

3. US FDA — Current Good Manufacturing Practice (cGMP) Regulations, 2026.

4. Blushwood Health — EBC-46 Lab Tests, 2026.